Remote Endarterectomy and Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease

Sponsor
Meshalkin Research Institute of Pathology of Circulation (Other)
Overall Status
Unknown status
CT.gov ID
NCT02948166
Collaborator
(none)
174
1
2
36
4.8

Study Details

Study Description

Brief Summary

Comparison of two methods for revascularization of the superficial femoral artery: remote endarterectomy vs. stenting of the superficial femoral artery cin patients with steno-occlusive lesion of the femoro-popliteal segment of TASC C, D

Condition or Disease Intervention/Treatment Phase
  • Procedure: Angioplasty with stenting of the femoral artery
  • Procedure: Open surgery
N/A

Detailed Description

Reported local percutaneous angioplasty and stenosis of femoral popliteal arteries indicate that the primary technical and clinical success above 95%. The technical success of recanalization of long occlusions femoral arteries less than 80%. Improvement of endovascular equipment designed for the treatment of total occlusions, increases the technical success of recanalization. The materials of the TASC II summarizes the results of several large studies that presented data on the operated segment artery patency at 56-73,7% within 2 years of observation. An alternative method of revascularization own femoral artery is remote endarterectomy. The two-year primary patency at remote endarterectomy is 86% (Moll F.L., Iio G.H. Closed superficial femoral artery endarterectomy: a 2-year follow up. Cardiovasc Surg. 1997; 5: 398-400). Primary assisted patency for 33 months 88% (Rosenthal D, Martin JD, Schubart PJ, Wellons ED. Remote. superficial femoral artery endarterectomy. J Cardiovasc Surg. (Torino) 2004; 45: 185-192). The length of the occlusion is not a limitation to the use of remote endarterectomy. Primary patency at 31 months was 60%.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
174 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Prospective Randomized Clinical Trial of the Remote Endarterectomy and the Femoral Arteries Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease (TASC C, D)
Study Start Date :
Jan 1, 2016
Anticipated Primary Completion Date :
Jan 1, 2018
Anticipated Study Completion Date :
Jan 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Stenting of the femoral artery

A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.

Procedure: Angioplasty with stenting of the femoral artery
A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.

Experimental: Open surgery

Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.

Procedure: Open surgery
Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.

Outcome Measures

Primary Outcome Measures

  1. the change of lumen in target vessel [Baseline, 3 days after the operation, 6 month, 12 month, 2, 3 years]

Secondary Outcome Measures

  1. Number of participants with a successful procedure of revascularization. [During the operation.]

  2. Number of participants with complications during the operation. [During the operation.]

  3. Number of participants with limb salvage [Baseline, 3 days after the operation, 6 month, 12 month, 2, 3 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with occlusive lesions of C and D type femoral artery and with chronic lower limb ischemia (II-IV degree by Fontaine, 4-6 degree by Rutherford)

  • Patients who consented to participate in this study.

Exclusion Criteria:
  • Chronic heart failure of III-IV functional class by NYHA classification.

  • Decompensated chronic "pulmonary" heart

  • Severe hepatic or renal failure (bilirubin> 35 mmol / l, glomerular filtration rate <60 mL / min);

  • Polyvalent drug allergy

  • Cancer in the terminal stage with a life expectancy less than 6 months;

  • Acute ischemic

  • Expressed aortic calcification tolerant to angioplasty

  • Patients with significant common femoral artery lesion

  • Patient refusal to participate or continue to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology Novosibirsk Russian Federation 630055

Sponsors and Collaborators

  • Meshalkin Research Institute of Pathology of Circulation

Investigators

  • Study Director: Andrey Karpenko, cientific-Research Institute of Circulation Pathology named after Academician E. Meshalkin

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Meshalkin Research Institute of Pathology of Circulation
ClinicalTrials.gov Identifier:
NCT02948166
Other Study ID Numbers:
  • N-RICP-468
First Posted:
Oct 28, 2016
Last Update Posted:
May 5, 2017
Last Verified:
May 1, 2017
Keywords provided by Meshalkin Research Institute of Pathology of Circulation

Study Results

No Results Posted as of May 5, 2017